Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: A positron emission tomographic study

Journal of Neurology Neurosurgery and Psychiatry

Volumn 65, Issue 2, 1998, Pages 155-163

  Asahina, Masato ^a,b   Suhara, Tetsuya ^a   Shinotoh, Hitoshi ^a,b   Inoue, Osamu ^a   Suzuki, Kazutoshi ^a   Hattori, Takamichi ^b  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Cognitive dysfunction; Muscarinic receptor; Parkinson's disease; Positron emission tomography; Progressive supranuclear palsy

Indexed keywords

1 METHYL 4 PIPERIDYL BENZILATE; CARBON 11; MUSCARINIC RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEMENTIA; DENERVATION; DISEASE SEVERITY; FEMALE; FOREBRAIN; FRONTAL CORTEX; HUMAN; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RECEPTOR BINDING;

EID: 0031828022     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.65.2.155     Document Type: Article

References (50)

1. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. Arch Neurol 1964;10:333-59.
2. Collins SJ, Ahlskog JE, Parisi JE, et al. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry 1995;58:167-73.
3. Albert ML, Feldman RG, Willis AL. The subcortical dementia of progressive supranuclear palsy. J Neurol Neurosurg Pychiatry 1974;37:121-30.
4. Brown RG, Marsden CD. Subcortical dementia: the neuropsychological evidence. Neuroscience 1988;25:363-87.
5. Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson's disease. Brain 1986;109:845-83.
6. Pillon B, Dubois B, Agid Y. Testing cognition may contribute to the diagnosis of movement disorders. Neurology 1996;46:329-34.
7. Ruberg M, Ploska A, Javoy-Agid F, et al. Muscarinic binding and choline acetyltransferase activity in parkinsonian subjects with reference to dementia. Brain Res 1982;232: 129-39.
8. Dubois B, Ruberg M, Jacovy-Agid F, et al. A subcorticocortical cholinergic system is affected in Parkinson's disease. Brain Res 1983;288:213-18.
9. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:413-21.
10. Lange KW, Wells FR, Jenner P, et al. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J Neurochem 1993;60:197-203.
11. Asahina M, Shinotoh H, Hirayama K, et al. Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. Acta Neurol Scand 1995;91:437-43.
12. Zweig RM, Whitehouse PJ, Casanova MF, et al. Loss of pedunculopontine neurons in progressive supranuclear palsy. Ann Neurol 1987;22:18-25.
13. Juncos JL, Hirsch EC, Malessa S, et al. Mesencephalic cholinergic nuclei in progressive supranuclear palsy. Neurology 1991;41:25-30.
14. Malessa S, Hirsch EC, Cervera P, et al. Progressive supranuclear palsy: loss of choline-acetyltransferase-like immunoreactive neurons in the pontine reticular formation. Neurology 1991;41:1593-7.
15. Tagliavini F, Pilleri G, Gemignani F, et al. Neuronal loss in the basal nucleus of Meynert in progressive supranuclear palsy. Acta Neuropathol (Berl) 1983;61:157-60.
16. Rogers JD, Brogan D, Mirra SS. The nucleus basalis of Meynert in neurological disease: a quantitative morphological study. Ann Neurol 1985;17:163-70.
17. Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's disease. In: Streifler MB, Korczyn AD, Melamed E, et al, eds. Advances in neurology. Vol 53. Parkinson's disease: anatomy, pathology, and therapy. New York: Raven Press, 1990:245-9.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed, revised. Washington, DC: APA, 1987.
19. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
20. Kashima H, Handa T, Kato M, et al. Neuropsychological investigation on chronic schizophrenia - aspects of its frontal functions. In: Takahashi R, Flor-Henry P, Gruzelier J, et al, eds. Cerebral dynamics, laterality and psychopathology. Amsterdam: Elsevier, 1987:337-45.
21. Matsui T, Hirano A. An atlas of the human brain for computerised tomography. Tokyo: Igaku Shoin, 1976.
22. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3:1-7.
23. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-90.
24. 3H]pirenzepine. J Neurochem 1986;46:274-9.
25. 11C]NMPB), a muscarinic acetylcholine receptor antagonist. Nucl Med Biol 1995;22:13-17.
26. Biel JH, Abood LG, Hoya WK, et al. Central stimulants. II. cholinergic blocking agents. Journal of Organic Chemistry 1961;26:4096-103.
27. Rehavi M, Yaavetz B, Kloog Y, et al. In vivo and in vitro studies on the antimuscarinic activity of some amino esters of benzilic acid. Biochem Pharmacol 1978;27:1117-24.
28. Otto CA, Mulholland GK, Perry SE, et al. In vitro and ex vivo evaluation of cyclic aminoalkyl benzilates as potential emission tomography ligands for the muscarinic receptor. Nucl Med Biol 1989;16:51-5.
29. Tejani-Butt SM, Luthin GR, Wolfe BB, et al. N-substituted derivatives of 4-piperidinyl benzilate: affinities for brain muscarinic acetylcholine receptors. Life Sci 1990;47:841-8.
30. 11]N-methyl-4-piperidyl benzilate binding to muscarinic cholinergic receptors. J Nucl Med 1992;33: 882.
31. Kloog Y, Egozi Y, Sokolovsky M. Characterization of muscarinic acetylcholine receptors from mouse brain: evidence for regional heterogeneity and isomerization. Mol Pharmacol 1979;15:545-58.
32. Ruberg M, Javoy-Agid F, Hirsch E, et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 1985;18:523-9.
33. Landwehrmeyer B, Palacios JM. Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy. J Neural Transm Suppl 1994;42: 229-16.
34. 11C-raclopride and positron emission tomography. Ann Neurol 1992;31:184-92.
35. Wolfson LJ, Leenders KL, Brown LL, et al. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. Neurology 1985;35:1399-105.
36. Jagust WJ, Reed BR, Martin EM, et al. Cognitive function and regional cerebral blood flow in Parkinson's disease. Brain 1992;115:521-37.
37. Leenders KL, Frackowiak RSJ, Lees AJ. Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. Brain 1988;111:615-30.
38. Dewey SL, Volkow ND, Logan J, et al. Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET). J Neurosci Res 1990;27:569-75.
39. Suhara T, Inoue O, Kobayashi K, et al. Age-related changes in human muscarinic acetylcholine receptors measured by positron emission tomography. Neurosci Lett 1993;149: 225-8.
40. 3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain. Synapse 1993;14:283-96.
41. Whitehouse PJ, Hedreen JC, White CL 3rd, et al. Basal forebrain neurons in the dementia of Parkinson's disease. Ann Neurol 1983;13:243-8.
42. Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984;15:415-8.
43. Kievit J, Kuypers HGJM. Basal forebrain and hypothalamic connections to frontal and parietal cortex in the Rhesus monkey. Science 1975;187:660-2.
44. Divac I. Magnocellular nuclei of the basal forebrain project to neocortex, brain stem, and olfactory bulb. Review of some functional correlates. Brain Res 1975;93:385-98.
45. Mesulam MM, Van Hoesen GW. Acetylcholinesterase-rich projections from the basal forebrain of the rhesus monkey to neocortex. Brain Res 1976;109:152-7.
46. Jones EG, Burton H, Saper CB, et al. Midbrain, diencephalic, and cortical relationships of the basal nucleus of Meynert and associated structures in primates. J Comp Neurol 1976;167:385-419.
47. Kish SJ, Chang LJ, Mirchandani L, et al. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol 1985;18:530-6.
48. Oyanagi K, Takahashi K, Wakabayashi K, et al. Selective decrease of large neurons in the neostriatum in progressive supranuclear palsy. Brain Res 1988;458:218-23
49. Wilcock GK, Esiri MM, Bowen DM, et al. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 1982;57:407-17.
50. Javoy-Agid F. Cholinergic and peptidergic systems in PSP. J Neural Transm Suppl 1994;42:205-18.